

## Appendix 1: (A)Early termination

### A Early termination

The justification for early termination of the trial: This was in large part due to the impact of the COVID pandemic on the transplantation program at the single site hosting the trial. Unfortunately, due to staff circumstances, we were unable to prolong the duration of the study to accommodate the resulting delay in recruitment.

The consequences of early termination for the evaluation of the results and for overall risk benefit assessment of the investigational medicinal product: Whilst the number of participants decreased, it was not thought to substantially decrease the scientific value of the study: the dose of IMP (AZD1656) required to trigger the primary endpoint (regulatory T cell migration to transplant kidneys) is not known, and hence the power calculation was speculative at the outset. There is still value in comparing the two cohorts - and especially with regard to impact on glycaemic control and on safety end-points. To this end, although recruitment closed early, it remained important to continue follow-up for the 1 year period post-transplantation in order to observe the long-term outcomes for the trial participants.